Search

A new report from the University of Texas MD Anderson Cancer Center discusses the complexities faced by clinicians when encountering a secondary SDHA pathogenic variant (PV) in patients without a personal or family history of SDHA-related tumors. The increasing use of germline multi-gene panel testing has led to a rise in these secondary findings, requiring a nuanced approach to counseling, surveillance, and decision-making. The report highlights the need for ongoing reassessment of surveillance approaches and provides practical recommendations for clinicians, including acknowledging the limitations of existing guidelines, fostering shared decision-making, and considering specialist referrals. The full article can be accessed for free through the provided link. [Extracted from the article]

Keywords: Alkanes; Aromatic Hydrocarbons; Catechols; Curcumin; Diarylheptanoids; Drugs and Therapies; Endocrine Cells; Endocrine Oncology; Endocrine Research; Health and Medicine; Hydrocarbons; Leydig Cells; Organic Chemicals; Testis EN Alkanes Aromatic Hydrocarbons Catechols Curcumin Diarylheptanoids Drugs and Therapies Endocrine Cells Endocrine Oncology Endocrine Research Health and Medicine Hydrocarbons Leydig Cells Organic Chemicals Testis 1279 1279 1 04/03/23 20230407 NES 230407 2023 APR 3 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators discuss new findings in endocrine oncology. Regarding curcumin's in vitro cytostatic capacity, we show that 40-80 mmol/L curcumin reduces MA-10 Leydig cells' proliferative capacity, which could be explained by the arrest in G2/M and the reduced viability due to the activation of the apoptotic pathway. The aim of this study was to assess curcumin's impact on Leydig cells' functions and its potential effect on LCT growth. [Extracted from the article]